KR20150088869A - 활성화 단백질 C(aPC)에 대한 모노클로날 항체 - Google Patents

활성화 단백질 C(aPC)에 대한 모노클로날 항체 Download PDF

Info

Publication number
KR20150088869A
KR20150088869A KR1020157017008A KR20157017008A KR20150088869A KR 20150088869 A KR20150088869 A KR 20150088869A KR 1020157017008 A KR1020157017008 A KR 1020157017008A KR 20157017008 A KR20157017008 A KR 20157017008A KR 20150088869 A KR20150088869 A KR 20150088869A
Authority
KR
South Korea
Prior art keywords
ser
gly
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157017008A
Other languages
English (en)
Korean (ko)
Inventor
샤오-얀 자오
줘쯔 왕
지안-밍 구
김지윤
맥신 바우존
존 이. 머피
커크 맥클린.
팡 진
토비아스 마쿼트
신쿠안 왕
안드레아스 빌맨
Original Assignee
바이엘 헬스케어 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 헬스케어 엘엘씨 filed Critical 바이엘 헬스케어 엘엘씨
Publication of KR20150088869A publication Critical patent/KR20150088869A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020157017008A 2012-11-29 2013-11-27 활성화 단백질 C(aPC)에 대한 모노클로날 항체 Withdrawn KR20150088869A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261731294P 2012-11-29 2012-11-29
US61/731,294 2012-11-29
US201361786472P 2013-03-15 2013-03-15
US61/786,472 2013-03-15
PCT/US2013/072243 WO2014085596A1 (en) 2012-11-29 2013-11-27 MONOCLONAL ANTIBODIES AGAISNT ACTIVATED PROTEIN C (aPC)

Publications (1)

Publication Number Publication Date
KR20150088869A true KR20150088869A (ko) 2015-08-03

Family

ID=50828462

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157017008A Withdrawn KR20150088869A (ko) 2012-11-29 2013-11-27 활성화 단백질 C(aPC)에 대한 모노클로날 항체

Country Status (18)

Country Link
US (1) US20150307625A1 (enExample)
EP (1) EP2925351A4 (enExample)
JP (1) JP2016501230A (enExample)
KR (1) KR20150088869A (enExample)
CN (1) CN104812402A (enExample)
AR (1) AR093671A1 (enExample)
AU (1) AU2013352159A1 (enExample)
BR (1) BR112015012414A2 (enExample)
CA (1) CA2892750A1 (enExample)
HK (1) HK1212896A1 (enExample)
IL (1) IL238658A0 (enExample)
MX (1) MX2015006424A (enExample)
RU (1) RU2015125349A (enExample)
SG (1) SG11201503719WA (enExample)
TW (1) TW201429992A (enExample)
UY (1) UY35154A (enExample)
WO (1) WO2014085596A1 (enExample)
ZA (1) ZA201504659B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087391A1 (en) * 2015-11-17 2017-05-26 Bayer Healthcare, Llc Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof
EP3831843A1 (en) * 2019-12-08 2021-06-09 Royal College Of Surgeons In Ireland A hemostatic agent and uses thereof
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
CN116496394B (zh) * 2022-01-26 2024-07-23 东莞市朋志生物科技有限公司 抗s100蛋白的抗体、检测s100蛋白的试剂和试剂盒
US20250163183A1 (en) * 2022-03-04 2025-05-22 Coagulant Therapeutics Corporation Camelid antibodies against activated protein c and uses thereof
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用
AU2024252640A1 (en) 2023-04-07 2025-10-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
DE69735421T2 (de) * 1996-04-24 2006-10-19 The Regents Of The University Of Michigan, Ann Arbor Gegen inaktivierung resistenter faktor viii
US6989241B2 (en) * 2000-10-02 2006-01-24 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein C and highly specific monoclonal antibody therefor
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US20030203355A1 (en) * 2002-04-24 2003-10-30 Los Alamos National Laboratory Fluorobodies: binding ligands with intrinsic fluorescence
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
WO2006017538A2 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
AU2005318171B2 (en) * 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
US7939637B2 (en) * 2005-12-13 2011-05-10 Medimmune Limited Insulin-like growth factor antibodies and uses thereof
US8039597B2 (en) * 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素(sclerostin)抗體組合物及使用方法
WO2009055669A2 (en) * 2007-10-26 2009-04-30 Oklahoma Medical Research Foundation Monoclonal antibodies against activated and unactivated protein c
GB0903151D0 (en) * 2009-02-25 2009-04-08 Bioinvent Int Ab Antibody uses and methods
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB201011771D0 (en) * 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
EP2640421A4 (en) * 2010-11-16 2014-05-28 Medimmune Llc THERAPIES FOR TREATMENTS WITH ANTI-IGF ANTIBODIES
US8440797B2 (en) * 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof

Also Published As

Publication number Publication date
AU2013352159A1 (en) 2015-06-04
AR093671A1 (es) 2015-06-17
RU2015125349A (ru) 2017-01-10
CN104812402A (zh) 2015-07-29
ZA201504659B (en) 2017-11-29
EP2925351A1 (en) 2015-10-07
US20150307625A1 (en) 2015-10-29
BR112015012414A2 (pt) 2017-09-12
JP2016501230A (ja) 2016-01-18
HK1212896A1 (zh) 2016-06-24
UY35154A (es) 2014-06-30
IL238658A0 (en) 2015-06-30
TW201429992A (zh) 2014-08-01
EP2925351A4 (en) 2016-08-24
MX2015006424A (es) 2015-08-14
WO2014085596A1 (en) 2014-06-05
CA2892750A1 (en) 2014-06-05
SG11201503719WA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
JP6684369B2 (ja) 組織因子経路インヒビター(tfpi)に対する最適化されたモノクローナル抗体
CA2933259C (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
JP6696899B2 (ja) プラスミノーゲン活性化因子阻害剤−1(pai−1)に対する抗体及びその使用
KR20150088869A (ko) 활성화 단백질 C(aPC)에 대한 모노클로날 항체
JP6170903B2 (ja) 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
TW201802121A (zh) 抗因子XI/XIa抗體之逆轉結合劑及其用途
JP6559188B2 (ja) 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
JP2018038398A (ja) 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
JP6419664B2 (ja) 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
AU2016269554B2 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
HK40017438A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK40017507A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
JP2018108089A (ja) 組織因子経路インヒビター(tfpi)に対するモノクローナル抗体
HK1156635A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK1156635B (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK1226645A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK1226645A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150625

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid